Compare PBYI & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | LANV |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | China |
| Employees | N/A | 2406 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 223.4M |
| IPO Year | N/A | N/A |
| Metric | PBYI | LANV |
|---|---|---|
| Price | $6.10 | $1.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 378.0K | 43.0K |
| Earning Date | 11-06-2025 | 08-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | $211,995,000.00 | ★ $341,783,911.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.90 |
| P/E Ratio | $8.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.58 | $1.38 |
| 52 Week High | $6.22 | $2.69 |
| Indicator | PBYI | LANV |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 47.86 |
| Support Level | $5.51 | $1.69 |
| Resistance Level | $5.73 | $1.80 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 98.31 | 54.55 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.